Phase III study shows enzalutamide offers significant benefit in prostate cancer
05:18 EDT 17 Aug 2012 | thePharmaLetter
USA-based Medivation (Nasdaq: MDVN) and Japanese drug major Astellas (TSE: 4503) has announced the publication in the New England Journal of Medicine of the results from the Phase III AFFIRM trial, an international, randomized, double-blind, placebo-..
Original Article: Phase III study shows enzalutamide offers significant benefit in prostate cancer
More From BioPortfolio on "Phase III study shows enzalutamide offers significant benefit in prostate cancer"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
